Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.

Abstract: The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to use of such peptides to generate binding molecules, such as antibodies, specific for the tau epitope and to such peptides and antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer’s disease.

Abstract: The invention relates to isolated synthetic or recombinant peptides comprising an epitope of human tau 2N4R, wherein the tau peptide sequence comprising the epitope is not phosphorylated. The invention also relates to use of such peptides to generate binding molecules, such as antibodies, specific for the non-phosphorylated tau epitopes and to such peptides and binding molecules, such as antibodies, for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.

Abstract: The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.

Abstract: The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.

Abstract: An expiring balance may be provided to a user account that the user can spend or pass along to a friend. The user may be given a limited time in which to spend the expiring balance after which the balance will not be available to the user. When the user decides to pass the balance along to a friend, an expiration time associated with the expiring balance may be reset. The expiring balance may be redeemed at participating locations and, if a location is not participating, the user may be able to notify an entity providing the expiring balance of the non-participation.

Abstract: The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.

Abstract: A composition based on cerium, zirconium and tungsten is described. The composition has a content expressed as an oxide, of which cerium is from 5% to 30% of the composition, tungsten is from 2% to 17% of the composition, and the remainder of the composition is zirconium. After aging at 750° C. under an air atmosphere including 10% water, it has a two-phase crystallographic structure having a tetragonal zirconia phase and a monoclinic zirconia phase, with no presence of a crystalline phase including tungsten. The composition can be used as a catalyst, especially in an SCR process.

Abstract: Heterocyclic compounds of formula (I) useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.

Abstract: The invention relates to a method for treating a gas containing nitrogen oxides (NOx), in which an NOx-reduction reaction is carried out using a nitrogen-containing reducing agent, which invention is characterized in that the catalyst used for the reduction reaction is a catalytic system containing a composition comprising zirconium, cerium and niobium in the following percentages by weight, expressed in terms of the weight of oxide: 10-50% of cerium, 5-20% of niobium and the remainder consisting of zirconium.

Abstract: An expiring balance may be provided to a user account that the user can spend or pass along to a friend. The user may be given a limited time in which to spend the expiring balance after which the balance will not be available to the user. When the user decides to pass the balance along to a friend, an expiration time associated with the expiring balance may be reset. The expiring balance may be redeemed at participating locations and, if a location is not participating, the user may be able to notify an entity providing the expiring balance of the non-participation.

Abstract: The present invention provides a method to obtain radiofluorinated compounds useful for in vivo imaging GABAA receptors. The method of the invention is high-yielding and may conveniently be carried out on an automated synthesizer such as Fastlab™. A further aspect of the invention is a cassette suitable for carrying out the automated method of synthesis of the invention. Novel precursor compounds useful in the method of the invention are also provided, as are a number of novel compounds obtained by the method of the invention.

Abstract: Pyridazinone compounds of Formula I: (I) wherein: R? is alkyl or Ar, optionally substituted with at least one alkyl, halogen, hydroxyl, alkoxy, haloalkoxy, acid, ester, amino, nitro, amide, or alkoxyhalo; 2 R is independently alkyi, alkynyl, ester, amino, amide, acid, aryl, heteroaryl, aminoalkyl, —C(=0)alkyl, —C(=0)aryl, —C(=0)heteroaryl, —C(=0)heterocycloalkyl, —C(=0)heterocycloalkylAr, —C(=0)(CH2)nhalo, —C(?O)(CH2)nheterocyclyl, or —SC?Ar, optionally substituted with at least one alkyi, alkylhalo, halogen, nitro, aryl, heteroaryl, or heteroaryl(CH2)nhalo; R3 and R4 are independently hydrogen, alkyi, alkenyl, alkynyl, aryl, heteroaryl; Ar is an aryl, heteroaryl, cycloalkyl, heterocycloalkyl group; n is an integer from 0-10; or a radiolabeled derivative thereof. The compounds are useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.

Abstract: A method is described for treating a gas including nitrogen oxides (NOx). The method can include conducting a reduction reaction of the nitrogen oxides with a nitrogen reducing agent. Further described, is a catalyst used for the reduction reaction which is a catalytic system including a composition based on cerium oxide and including niobium oxide in a proportion by a mass of from 2% to 20%.

Abstract: The invention relates to a method for treating a gas containing nitrogen oxides (NOx), in which an NOx-reduction reaction is carried out using a nitrogen-containing reducing agent, which invention is characterized in that the catalyst used for the reduction reaction is a catalytic system containing a composition comprising zirconium, niobium in the following percentages by weight, expressed in terms of the weight of oxide: 10-50% of cerium, 5-20% of niobium and the remainder consisting of zirconium.

Abstract: Heterocyclic compounds of formula (I) useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.

Abstract: Radiolabeled compounds useful as diagnostic imaging agents of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.

Abstract: A method is described for treating a gas including nitrogen oxides (NOx). The method can include conducting a reduction reaction of the nitrogen oxides with a nitrogen reducing agent. Further described, is a catalyst used for the reduction reaction which is a catalytic system including a composition based on cerium oxide and including niobium oxide in a proportion by a mass of from 2% to 20%.

Abstract: A composition based on cerium, zirconium and tungsten is described. The composition has a content expressed as an oxide, of which cerium is from 5% to 30% of the composition, tungsten is from 2% to 17% of the composition, and the remainder of the composition is zirconium. After aging at 750° C. under an air atmosphere including 10% water, it has a two-phase crystallographic structure having a tetragonal zirconia phase and a monoclinic zirconia phase, with no presence of a crystalline phase including tungsten. The composition can be used as a catalyst, especially in an SCR process.

Abstract: The present invention provides a method to obtain radiofluorinated compounds useful for in vivo imaging GABAA receptors. The method of the invention is high-yielding and may conveniently be carried out on an automated synthesizer such as Fastlab™. A further aspect of the invention is a cassette suitable for carrying out the automated method of synthesis of the invention. Novel precursor compounds useful in the method of the invention are also provided, as are a number of novel compounds obtained by the method of the invention.